Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle
Open Access

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang and Richard J. Riese
The Journal of Rheumatology May 2014, 41 (5) 837-852; DOI: https://doi.org/10.3899/jrheum.130683
Jürgen Wollenhaupt
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Wollenhaupt{at}rheumatologikum.de
Joel Silverfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eun Bong Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey R. Curtis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan P. Wood
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koshika Soma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chudy I. Nduaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgitta Benda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Gruben
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Nakamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihiro Komuro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel H. Zwillich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisy Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Riese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Information

vol. 41 no. 5 837-852
DOI 
https://doi.org/10.3899/jrheum.130683
PubMed 
24692527

Published By 
The Journal of Rheumatology
Print ISSN 
0315-162X
Online ISSN 
1499-2752
History 
  • Accepted for publication November 19, 2013
  • Published online May 1, 2014.

Article Versions

  • Latest version (April 1, 2014 - 04:00).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2014 Free online via JRheum Full Release option

Author Information

  1. Jürgen Wollenhaupt⇑,
  2. Joel Silverfield,
  3. Eun Bong Lee,
  4. Jeffrey R. Curtis,
  5. Susan P. Wood,
  6. Koshika Soma,
  7. Chudy I. Nduaka,
  8. Birgitta Benda,
  9. David Gruben,
  10. Hiroyuki Nakamura,
  11. Yoshihiro Komuro,
  12. Samuel H. Zwillich,
  13. Lisy Wang and
  14. Richard J. Riese
  1. From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan.
  2. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc.
  1. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt{at}rheumatologikum.de

Article usage

Article usage: March 2014 to October 2025

AbstractFullPdf
Mar 2014101
Apr 20146217621
May 20141405352458
Jun 2014355214227
Jul 2014183187179
Aug 201414012494
Sep 2014124151151
Oct 2014130136110
Nov 201411292109
Dec 2014818191
Jan 20158899105
Feb 201599113114
Mar 201589133122
Apr 201568114121
May 20158010589
Jun 20157110496
Jul 20155613090
Aug 201581106111
Sep 201568123124
Oct 20156310083
Nov 20155210269
Dec 20155712794
Jan 201663150110
Feb 201666105102
Mar 201663137126
Apr 201684128114
May 20164711190
Jun 2016529983
Jul 2016609087
Aug 20167610286
Sep 2016568178
Oct 20168510199
Nov 20166610478
Dec 2016142168124
Jan 201743780226
Feb 201722808103
Mar 201725671123
Apr 201736523104
May 201744552133
Jun 20172245395
Jul 20172129982
Aug 201745149147
Sep 201732104125
Oct 201744154160
Nov 201736147109
Dec 20172820878
Jan 20183816481
Feb 2018339992
Mar 2018309974
Apr 20183010487
May 20182112082
Jun 20181610693
Jul 20182717191
Aug 20181912777
Sep 20181312769
Oct 20183912956
Nov 201824128138
Dec 20181913746
Jan 20192818171
Feb 201936167133
Mar 20193815361
Apr 20192116058
May 20191312240
Jun 2019178875
Jul 20191811744
Aug 20193924954
Sep 2019257647
Oct 2019207351
Nov 2019177653
Dec 2019197657
Jan 2020308543
Feb 2020169164
Mar 2020188049
Apr 20202612072
May 2020157031
Jun 2020248558
Jul 2020218348
Aug 2020347252
Sep 2020246837
Oct 2020186746
Nov 2020207350
Dec 2020208739
Jan 2021235443
Feb 2021317549
Mar 2021258759
Apr 2021446375
May 20215713440
Jun 2021297152
Jul 2021106132
Aug 2021267842
Sep 2021169948
Oct 20211410157
Nov 2021199257
Dec 2021148927
Jan 2022197836
Feb 2022166432
Mar 2022389032
Apr 20224611844
May 2022179448
Jun 2022168635
Jul 202286433
Aug 2022307325
Sep 2022176819
Oct 2022276324
Nov 2022208538
Dec 202294913
Jan 20231511844
Feb 2023167126
Mar 20232310141
Apr 2023235348
May 2023207966
Jun 2023197028
Jul 2023187148
Aug 2023217647
Sep 20231114124
Oct 20232228534
Nov 20232733344
Dec 20233122577
Jan 202458131150
Feb 20241610443
Mar 20242115549
Apr 20241513653
May 20243530731
Jun 2024228331
Jul 20241913227
Aug 2024198320
Sep 2024158123
Oct 20241311229
Nov 20241610734
Dec 2024178925
Jan 2025167425
Feb 20251513444
Mar 2025616532
Apr 20251611039
May 20251317736
Jun 20252624029
Jul 20251624048
Aug 20251717854
Sep 20252016453
Oct 20252513132

Statistics from Altmetric.com

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 5
1 May 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang, Richard J. Riese
The Journal of Rheumatology May 2014, 41 (5) 837-852; DOI: 10.3899/jrheum.130683

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang, Richard J. Riese
The Journal of Rheumatology May 2014, 41 (5) 837-852; DOI: 10.3899/jrheum.130683
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Keywords

TOFACITINIB
ANTIRHEUMATIC AGENTS
RHEUMATOID ARTHRITIS
CLINICAL TRIAL

Related Articles

Cited By...

More in this TOC Section

  • Do Monosodium Urate Crystals Reduce at Different Rates in Joints and Tendons During Urate-Lowering Therapy? A Dual-Energy Computed Tomography Study
  • Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events
  • Association of Patient Resilience With Patient-Reported Physical and Mental/Emotional Quality of Life in Systemic Lupus Erythematosus
Show more Article

Similar Articles

Keywords

  • TOFACITINIB
  • antirheumatic agents
  • rheumatoid arthritis
  • clinical trial

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire